NSC Research Inc

1. Eli Lilly and Company $909,744 18 payments
2. Boehringer Ingelheim Pharmaceuticals, Inc. $228,930 15 payments
3. Esperion Therapeutics, Inc. $55,172 108 payments
4. Kowa Research Institute, Inc. $31,238 17 payments
5. Novartis Pharmaceuticals Corporation $6,231 2 payments
6. Janssen Research & Development, LLC $4,730 2 payments
7. Organon LLC $3,500 2 payments

1. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity $327,323 5 payments
2. A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity $300,931 2 payments
3. The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (Surpass Cvot) $250,697 9 payments
4. Obesity Long term safety in patients with CV risk $128,604 1 payment
5. A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD $100,326 14 payments
6. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (Etc-1002) on the Occurrence of Major Cardiovascular Events in Patients With, Or at High Risk For, Cardiovascular Disease Who Are Statin Intolerant $55,172 108 payments
7. The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (Surpass Cvot) $30,794 2 payments
8. K-877-302 $27,849 15 payments
9. Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor Arni Versus Ace Inhibitor Trial to Determine Impact on Serious Events After Myocardial Infarction Paradise Mi $6,231 2 payments
10. A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes $4,730 2 payments

1. Patient care $3,500 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.